Patent Expiry

Patent/Exclusivity Expiry: CABOMETYX

Other upcoming events for EXEL

Phase 3 ReadoutPhase 3 Topline: A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants
Phase 3 ReadoutPhase 3 Topline: Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Patent ExpiryPatent/Exclusivity Expiry: COMETRIQ
Patent ExpiryPatent/Exclusivity Expiry: COTELLIC

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Patent/Exclusivity Expiry: CABOMETYX — EXEL Patent Expiry | BioSniper